Skip to main content
. 2019 Mar 27;21(4):413–427. doi: 10.1016/j.neo.2019.03.003

Figure 2.

Figure 2

LOXL2 promotes the invasion and tube formation of LECs. (A) Representative and quantified results showing the relative invasion activity of the hLECs treated with the LOXL2 protein. (B) Representative and quantified results showing the relative tube formation activity of the hLECs treated with the LOXL2 protein. (C, D) Quantified results showing the relative invasion and tube formation activity of the hLECs treated with MCF7-LV CM or MCF7-LOXL2 CM in the presence of IgG or LOXL2-antibodies. (E, F) Quantified results showing the relative invasion and tube formation activity of the hLECs treated with MDA231-LV CM or MDA231-shLOXL2 CM in the presence of LOXL2 or BSA. Scale bar = 200 μm. (G) Representative photomicrographs showing LOXL2-induced lymphatic vessel formation in a Matrigel plug assay. Plugs containing the different dose of LOXL2 into the abdominal midline of BALB/c mice. After 8 days, IF staining of lymphatic vessels in dissected Matrigel plugs was performed. LYVE-1 (green) represents lymphatic vessels (left; Scale bar = 100 μm). Quantified results were shown (right; n = 6). (H) Density of lymphatic vessels in the Matrigel plug assay. Plugs containing indicated reagents were subcutaneously injected into BALB/c mice. After 8 days, plugs were dissected and applied to IF analysis for lymphatic vessel density. LYVE-1 (green) represents lymphatic vessels. (Scale bar = 100 μm). (I) Quantified results were shown (n = 6). The data are the means ± SD of three independent experiments.*P < .05; **P < .01; ***P < .001.